Cytokinetics, Incorporated (NASDAQ:CYTK) Files An 8-K Other Events
Item 8.01. Other Events.

Cytokinetics, Incorporated today announced the start of a Phase 1b, double-blind, randomized, placebo-controlled, multiple dose, two-period crossover study to assess the effect of CK-2127107 on measures of physical function in elderly adults with limited mobility. CK-2127107 is a next-generation fast skeletal muscle troponin activator (FSTA) which is being developed as a potential treatment for people living with spinal muscular atrophy (SMA), chronic obstructive pulmonary disease (COPD) and certain other debilitating diseases and conditions associated with muscular weakness and/or fatigue. Astellas is conducting this Phase 1b clinical trial in collaboration with Cytokinetics.

Item 9.01. Financial Statements and Exhibits.

Exhibit 99.1. Press release dated June 29, 2017

CYTOKINETICS INC Exhibit
EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFilingEXHIBIT 99.1Cytokinetics Announces Start of Phase 1b Clinical Trial of  CK-2127107 in Elderly Subjects With Limited MobilityTrial Designed to Assess Effects of Skeletal Muscle Activation  on Measures of Muscle Strength and Endurance Under Collaboration with Astellas SOUTH SAN FRANCISCO,…
To view the full exhibit click here
About Cytokinetics, Incorporated (NASDAQ:CYTK)

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.